European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis

Celltrion Healthcare announced that the European Commission has granted marketing authorisation for Remsima® subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion]
Press Release

Continue reading “European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis”

Bookmark

No account yet? Register

0
Share

Single-Cell Atlas of Colonic CD8+ T Cells in Ulcerative Colitis

Scientists compiled an unbiased atlas of human colonic CD8+ T cells in health and ulcerative colitis using single-cell transcriptomics with T-cell receptor repertoire analysis and mass cytometry.
[Nature Medicine]
Corridoni, D., Antanaviciute, A., Gupta, T., Fawkner-Corbett, D., Aulicino, A., Jagielowicz, M., Parikh, K., Repapi, E., Taylor, S., Ishikawa, D., Hatano, R., Yamada, T., Xin, W., Slawinski, H., Bowden, R., Napolitani, G., Brain, O., Morimoto, C., Koohy, H., & Simmons, A. (2020). Single-cell atlas of colonic CD8 + T cells in ulcerative colitis. Nature Medicine, 1–11. https://doi.org/10.1038/s41591-020-1003-4 Cite
Abstract

Continue reading “Single-Cell Atlas of Colonic CD8+ T Cells in Ulcerative Colitis”

Bookmark

No account yet? Register

0
Share

European Commission Grants Marketing Authorisation for World’s First Subcutaneous Formulation of Infliximab, Remsima® SC, for an Additional Five Indications including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis

Celltrion Healthcare announced that the European Commission has granted marketing authorisation for Remsima® subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion Healthcare ]
Press Release

Continue reading “European Commission Grants Marketing Authorisation for World’s First Subcutaneous Formulation of Infliximab, Remsima® SC, for an Additional Five Indications including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis”

Bookmark

No account yet? Register

0
Share

Mylan and Fujifilm Kyowa Kirin Biologics Announce US FDA Approval of Hulio® (adalimumab-fkjp)

Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the FDA has approved Hulio® for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.
[Mylan]
Press Release

Continue reading “Mylan and Fujifilm Kyowa Kirin Biologics Announce US FDA Approval of Hulio® (adalimumab-fkjp)”

Bookmark

No account yet? Register

1+
Share

Role of Inflammation in Pathophysiology of Colonic Disease: An Update

The authors provide an update on the literature to understand how genetics, diet, and the gut microbiota influence the crosstalk between immune and non-immune cells resulting in inflammation observed in multiple colonic pathologies.
[International Journal of Molecular Sciences]
Full Article

Continue reading “Role of Inflammation in Pathophysiology of Colonic Disease: An Update”

Bookmark

No account yet? Register

0
Share

Intestinal Epithelial Expression of MHCII Determines Severity of Chemical, T Cell-Induced, and Infectious Colitis in Mice

In mice with dextran sodium sulfate or T cell-induced colitis, loss of histocompatibility complex class II (MHCII) from Intestinal epithelial cells reduced but does not eliminated mucosal inflammation. However, in mice with C rodentium-induced colitis, loss of MHCII reduced bacterial clearance by decreasing binding of IgA to commensal and pathogenic bacteria.
[Gastroenterology]
Abstract

Continue reading “Intestinal Epithelial Expression of MHCII Determines Severity of Chemical, T Cell-Induced, and Infectious Colitis in Mice”

Bookmark

No account yet? Register

0
Share

Epithelial-Derived Gasdermin D Mediates Nonlytic IL-1β Release during Experimental Colitis

Scientists report a nonpyroptotic role of full-length Gasdermin D in guiding the release of IL-1β–containing small extracellular vesicles from intestinal epithelial cells .
[Journal of Clinical Investigation]
Full ArticleGraphical Abstract

Continue reading “Epithelial-Derived Gasdermin D Mediates Nonlytic IL-1β Release during Experimental Colitis”

Bookmark

No account yet? Register

0
Share

Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease

Celltrion Healthcare announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanding the existing marketing authorisation for the subcutaneous formulation of Remsima® in an additional five indications: for the treatment of patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion]
Press Release

Continue reading “Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease”

Bookmark

No account yet? Register

0
Share

CD47 Is a Negative Regulator of Intestinal Epithelial Cell Self-Renewal Following Dss-Induced Experimental Colitis

Scientists revealed CD47 as a negative regulator in intestinal epithelial cell renewal during colitis through downregulating OSKM transcriptional factors.
[Scientific Reports]
Full Article

Continue reading “CD47 Is a Negative Regulator of Intestinal Epithelial Cell Self-Renewal Following Dss-Induced Experimental Colitis”

Bookmark

No account yet? Register

0
Share

Difference in Presence and Number of CD83+ Dendritic Cells in Patients with Ulcerative Colitis and Crohn’s Disease

There were 154 subjects included in this study: 60 with ulcerative colitis, 19 with Crohn’s disease and 75 in the control group. Colonic biopsy was performed in all subjects. Specimens were incubated with a primary anti-CD83 antibody.
[Scientific Reports]
Full Article

Continue reading “Difference in Presence and Number of CD83+ Dendritic Cells in Patients with Ulcerative Colitis and Crohn’s Disease”

Bookmark

No account yet? Register

0
Share

Latexin Deficiency in Mice Up-Regulates Inflammation and Aggravates Colitis through hECTD1/Rps3/Nf-κB Pathway

Ectopic expression of Latexin led to IκBα accumulation in intestinal epithelial cells, however, latexin knockdown enhanced the interaction of HECTD1 and Rps3, contributing to the ubiquitination degradation of IκBα, and subsequently enhanced inflammatory response.
[Scientific Reports]
Full Article

Continue reading “Latexin Deficiency in Mice Up-Regulates Inflammation and Aggravates Colitis through hECTD1/Rps3/Nf-κB Pathway”

Bookmark

No account yet? Register

0
Share

Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine for the Treatment of Ulcerative Colitis

Devonian Health Group, Inc. announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S patent application titled, “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease,” covering the use of Thykamine for the treatment of ulcerative colitis.
[Devonian]
Press Release

Continue reading “Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine for the Treatment of Ulcerative Colitis”

Bookmark

No account yet? Register

0
Share
Share